Philadelphia Chromosome Positive Chronic Myeloid Leukemia Ph Cml — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for philadelphia chromosome positive chronic myeloid leukemia ph cml . 12 active patents protecting 1 drugs from 1+ originators. First major cliff: 2035. Daily refresh.

1
Approved drugs
12
Active US patents
53/100
Avg vulnerability
—
Annual revenue covered

Originators in Philadelphia Chromosome Positive Chronic Myeloid Leukemia Ph Cml

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Novartis 12 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating philadelphia chromosome positive chronic myeloid leukemia ph cml . Each bar = one year. Y-axis scaled to peak year (9 patents).

3
35
9
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Scemblix
ASCIMINIB HYDROCHLORIDE
 Novartis 12 53 — 2035-10-29

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8829195 Scemblix method of use 75 2035-10-29
12252479 Scemblix method of use 75 2040-05-17
12252479 Scemblix method of use 75 2040-05-17
12252479 Scemblix method of use 75 2040-05-17
8829195 Scemblix method of use 62 2035-10-29
8829195 Scemblix method of use 62 2035-10-29
12252478 Scemblix formulation 55 2040-05-14
12252478 Scemblix formulation 55 2040-05-14
12252478 Scemblix formulation 55 2040-05-14
11407735 Scemblix composition of matter 17 2040-05-14

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11407735 Scemblix composition of matter 12 2040-05-14
11407735 Scemblix composition of matter 12 2040-05-14
11407735 Scemblix composition of matter 17 2040-05-14
12252478 Scemblix formulation 55 2040-05-14
12252478 Scemblix formulation 55 2040-05-14
12252478 Scemblix formulation 55 2040-05-14
8829195 Scemblix method of use 62 2035-10-29
8829195 Scemblix method of use 62 2035-10-29
12252479 Scemblix method of use 75 2040-05-17
12252479 Scemblix method of use 75 2040-05-17

Related